Margetuximab Expanded Access Program
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: HER2-positive Breast Cancer|HER2-positive Carcinoma
Interventions: BIOLOGICAL: Margetuximab
Sponsor: MacroGenics